A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers (English)
- New search for: Chi, K. N.
- New search for: Yu, E. Y.
- New search for: Jacobs, C.
- New search for: Bazov, J.
- New search for: Kollmannsberger, C.
- New search for: Higano, C. S.
- New search for: Mukherjee, S. D.
- New search for: Gleave, M. E.
- New search for: Stewart, P. S.
- New search for: Hotte, S. J.
- New search for: Chi, K. N.
- New search for: Yu, E. Y.
- New search for: Jacobs, C.
- New search for: Bazov, J.
- New search for: Kollmannsberger, C.
- New search for: Higano, C. S.
- New search for: Mukherjee, S. D.
- New search for: Gleave, M. E.
- New search for: Stewart, P. S.
- New search for: Hotte, S. J.
In:
ANNALS OF ONCOLOGY
;
27
, 6
;
1116-1122
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
-
Contributors:Chi, K. N. ( author ) / Yu, E. Y. ( author ) / Jacobs, C. ( author ) / Bazov, J. ( author ) / Kollmannsberger, C. ( author ) / Higano, C. S. ( author ) / Mukherjee, S. D. ( author ) / Gleave, M. E. ( author ) / Stewart, P. S. ( author ) / Hotte, S. J. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27, 6 ; 1116-1122
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:7 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 6
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 961
-
Lessons from clinical trials on quality-of-life assessment in ovarian cancer trialsDi Maio, M. / Perrone, F. et al. | 2016
- 962
-
Diagnostic Gleason score and castration-resistant prostate cancerJayaram, A. / Attard, G. et al. | 2016
- 965
-
Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivorsAbrahams, H. J. / Gielissen, M. F. / Schmits, I. C. / Verhagen, C. A. / Rovers, M. M. / Knoop, H. et al. | 2016
- 975
-
Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature reviewHager, S. / Ackermann, C. J. / Joerger, M. / Gillessen, S. / Omlin, A. et al. | 2016
- 984
-
Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence?Khan, A. A. / Khan, Z. / Warnakulasuriya, S. et al. | 2016
- 998
-
Ocular toxicities of MEK inhibitors and other targeted therapiesStjepanovic, N. / Velazquez-Martin, J. P. / Bedard, P. L. et al. | 2016
- 1006
-
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)†Fujiwara, K. / Monk, B. J. / Lhommé, C. / Coleman, R. L. / Brize, A. / Oaknin, A. / Ray-Coquard, I. / Fabbro, M. / Provencher, D. / Bamias, A. et al. | 2016
- 1013
-
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyMatulonis, U. A. / Penson, R. T. / Domchek, S. M. / Kaufman, B. / Shapira-Frommer, R. / Audeh, M. W. / Kaye, S. / Molife, L. R. / Gelmon, K. A. / Robertson, J. D. et al. | 2016
- 1020
-
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group studyTrédan, O. / Follana, P. / Moullet, I. / Cropet, C. / Trager-Maury, S. / Dauba, J. / Lavau-Denes, S. / Diéras, V. / Béal-Ardisson, D. / Gouttebel, M. et al. | 2016
- 1029
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer†Michiels, S. / Pugliano, L. / Marguet, S. / Grun, D. / Barinoff, J. / Cameron, D. / Cobleigh, M. / Di Leo, A. / Johnston, S. / Gasparini, G. et al. | 2016
- 1035
-
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2− early breast cancer: WSG-AGO EC-Doc TrialGluz, O. / Liedtke, C. / Huober, J. / Peyro-Saint-Paul, H. / Kates, R. E. / Kreipe, H. H. / Hartmann, A. / Pelz, E. / Erber, R. / Mohrmann, S. et al. | 2016
- 1041
-
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trialMackey, J. R. / Pieńkowski, T. / Crown, J. / Sadeghi, S. / Martin, M. / Chan, A. / Saleh, M. / Sehdev, S. / Provencher, L. / Semiglazov, V. et al. | 2016
- 1047
-
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trialHarbeck, N. / Iyer, S. / Turner, N. / Cristofanilli, M. / Ro, J. / André, F. / Loi, S. / Verma, S. / Iwata, H. / Bhattacharyya, H. et al. | 2016
- 1055
-
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOXCiardiello, F. / Normanno, N. / Martinelli, E. / Troiani, T. / Pisconti, S. / Cardone, C. / Nappi, A. / Bordonaro, A. R. / Rachiglio, M. / Lambiase, M. et al. | 2016
- 1062
-
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancerAmatu, A. / Barault, L. / Moutinho, C. / Cassingena, A. / Bencardino, K. / Ghezzi, S. / Palmeri, L. / Bonazzina, E. / Tosi, F. / Ricotta, R. et al. | 2016
- 1068
-
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials†Overman, M. J. / Morris, V. / Kee, B. / Fogelman, D. / Xiao, L. / Eng, C. / Dasari, A. / Shroff, R. / Mazard, T. / Shaw, K. et al. | 2016
- 1074
-
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safetyLuo, H. Y. / Li, Y. H. / Wang, W. / Wang, Z. Q. / Yuan, X. / Ma, D. / Wang, F. H. / Zhang, D. S. / Lin, D. R. / Lin, Y. C. et al. | 2016
- 1081
-
Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemiaYoon, J. H. / Yhim, H. Y. / Kwak, J. Y. / Ahn, J. S. / Yang, D. H. / Lee, J. J. / Kim, S. J. / Kim, J. S. / Park, S. J. / Choi, C. W. et al. | 2016
- 1088
-
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†Robinson, S. P. / Boumendil, A. / Finel, H. / Schouten, H. / Ehninger, G. / Maertens, J. / Crawley, C. / Rambaldi, A. / Russell, N. / Anders, W. et al. | 2016
- 1095
-
The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study†Alzahrani, M. / El-Galaly, T. C. / Hutchings, M. / Hansen, J. W. / Loft, A. / Johnsen, H. E. / Iyer, V. / Wilson, D. / Sehn, L. H. / Savage, K. J. et al. | 2016
- 1100
-
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemiaFalchi, L. / Vitale, C. / Keating, M. J. / Lerner, S. / Wang, X. / Elhor Gbito, K. Y. / Strom, S. / Wierda, W. G. / Ferrajoli, A. et al. | 2016
- 1107
-
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioidsCorli, O. / Floriani, I. / Roberto, A. / Montanari, M. / Galli, F. / Greco, M. T. / Caraceni, A. / Kaasa, S. / Dragani, T. A. / Azzarello, G. et al. | 2016
- 1116
-
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancersChi, K. N. / Yu, E. Y. / Jacobs, C. / Bazov, J. / Kollmannsberger, C. / Higano, C. S. / Mukherjee, S. D. / Gleave, M. E. / Stewart, P. S. / Hotte, S. J. et al. | 2016
- 1123
-
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomasGaudio, E. / Tarantelli, C. / Kwee, I. / Barassi, C. / Bernasconi, E. / Rinaldi, A. / Ponzoni, M. / Cascione, L. / Targa, A. / Stathis, A. et al. | 2016
- 1129
-
Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, ChinaHuang, Z. / Wen, W. / Zheng, Y. / Gao, Y. T. / Wu, C. / Bao, P. / Wang, C. / Gu, K. / Peng, P. / Gong, Y. et al. | 2016
- 1135
-
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaSpain, L. / Higgins, R. / Gopalakrishnan, K. / Turajlic, S. / Gore, M. / Larkin, J. et al. | 2016
- 1138
-
Targeted treatment and immunotherapy in leptomeningeal metastases from melanomaGeukes Foppen, M. H. / Brandsma, D. / Blank, C. U. / van Thienen, J. V. / Haanen, J. B. / Boogerd, W. et al. | 2016
- 1143
-
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)Kanai, M. / Kawaguchi, T. / Kotaka, M. / Shinozaki, K. / Touyama, T. / Manaka, D. / Ishigure, K. / Hasegawa, J. / Munemoto, Y. / Matsui, T. et al. | 2016
- 1148
-
A genomic case study of mixed fibrolamellar hepatocellular carcinomaGriffith, O. L. / Griffith, M. / Krysiak, K. / Magrini, V. / Ramu, A. / Skidmore, Z. L. / Kunisaki, J. / Austin, R. / McGrath, S. / Zhang, J. et al. | 2016
- 1155
-
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case studyMorrow, C. J. / Trapani, F. / Metcalf, R. L. / Bertolini, G. / Hodgkinson, C. L. / Khandelwal, G. / Kelly, P. / Galvin, M. / Carter, L. / Simpson, K. L. et al. | 2016
- 1161
-
Rociletinib: has the TIGER lost a few of its stripes?Dhingra, K. et al. | 2016
- 1165
-
Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and developmentYver, A. et al. | 2016
- 1171
-
Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Hines et al.Rosati, G. / Mosconi, P. / Torri, V. / Apolone, G. / Johnson, F. E. / Fossati, R. et al. | 2016
- 1171
-
What is the clinical impact of the LUX-Lung 5 trial?Addeo, A. et al. | 2016
- 1172
-
Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by AddeoSchuler, M. / Yang, J. C. / Planchard, D. et al. | 2016
- 1173
-
Reply to the letter to the editor ‘Survival in young adults diagnosed with follicular lymphoma’ by Calvo et al.Conconi, A. / Montoto, S. / Montserrat, E. / Zucca, E. et al. | 2016
- 1174
-
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanomaLee, B. / Wong, A. / Kee, D. / Neeson, P. / Shackleton, M. / McArthur, G. / Sandhu, S. et al. | 2016
- 1177
-
On the tumor risk from dental diagnostic X-ray exposureJargin, S. V. et al. | 2016
- 1177
-
Reply to the letter to the editor ‘On the tumor risk from dental diagnostic X-ray exposure’ by JarginLin, M. C. / Lee, C. F. / Kao, C. H. et al. | 2016
- 1178
-
Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumabCousin, S. / Toulmonde, M. / Kind, M. / Cazeau, A. L. / Bechade, D. / Coindre, J. M. / Italiano, A. et al. | 2016
- 1180
-
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerO'Neil, B. H. / Scott, A. J. / Ma, W. W. / Cohen, S. J. / Aisner, D. L. / Menter, A. R. / Tejani, M. A. / Cho, J. K. / Granfortuna, J. / Coveler, A. L. et al. | 2016
- 1181
-
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancersLi, J. / Holm, J. / Bergh, J. / Eriksson, M. / Darabi, H. / Lindström, L. S. / Törnberg, S. / Hall, P. / Czene, K. et al. | 2016